Ionis Pharmaceuticals’ (IONS) “Outperform” Rating Reaffirmed at BMO Capital Markets

BMO Capital Markets reaffirmed their outperform rating on shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in a research note issued to investors on Tuesday morning. The brokerage currently has a $62.00 price objective on the stock.

IONS has been the subject of several other reports. Leerink Swann reissued an outperform rating and issued a $45.00 price target (down from $47.00) on shares of Ionis Pharmaceuticals in a report on Wednesday, May 17th. TheStreet raised Ionis Pharmaceuticals from a d+ rating to a c- rating in a report on Wednesday, July 5th. Vetr cut Ionis Pharmaceuticals from a hold rating to a sell rating and set a $37.67 price target for the company. in a report on Monday, March 27th. Piper Jaffray Companies set a $51.00 price target on Ionis Pharmaceuticals and gave the company a buy rating in a report on Wednesday, May 10th. Finally, Needham & Company LLC reissued a buy rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a report on Wednesday, May 17th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $44.55.

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) traded down 0.69% on Tuesday, hitting $54.33. The stock had a trading volume of 1,482,874 shares. Ionis Pharmaceuticals has a one year low of $24.58 and a one year high of $59.71. The firm’s 50-day moving average is $52.42 and its 200-day moving average is $46.57. The company’s market cap is $6.74 billion.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Tuesday, May 9th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.13. The business had revenue of $110.30 million during the quarter, compared to analysts’ expectations of $86.03 million. Ionis Pharmaceuticals had a negative return on equity of 14.61% and a negative net margin of 4.80%. The company’s quarterly revenue was up 199.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.52) EPS. On average, analysts expect that Ionis Pharmaceuticals will post ($0.27) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2017/07/26/ionis-pharmaceuticals-ions-outperform-rating-reaffirmed-at-bmo-capital-markets.html.

In related news, major shareholder Ionis Pharmaceuticals Inc purchased 3,125,000 shares of the business’s stock in a transaction dated Wednesday, July 19th. The stock was bought at an average cost of $8.00 per share, with a total value of $25,000,000.00. Following the completion of the acquisition, the insider now directly owns 28,884,540 shares in the company, valued at approximately $231,076,320. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Chairman Stanley T. Crooke sold 11,000 shares of the business’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $55.35, for a total value of $608,850.00. Following the completion of the transaction, the chairman now directly owns 48,014 shares of the company’s stock, valued at $2,657,574.90. The disclosure for this sale can be found here. Over the last three months, insiders sold 45,029 shares of company stock valued at $2,384,840. Insiders own 1.86% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in IONS. Hanseatic Management Services Inc. bought a new position in Ionis Pharmaceuticals during the first quarter worth $138,000. Westpac Banking Corp bought a new position in Ionis Pharmaceuticals during the first quarter worth $171,000. Cheyne Capital Management UK LLP bought a new position in Ionis Pharmaceuticals during the second quarter worth $249,000. Capstone Asset Management Co. boosted its position in Ionis Pharmaceuticals by 10.3% in the first quarter. Capstone Asset Management Co. now owns 5,148 shares of the company’s stock worth $207,000 after buying an additional 480 shares during the period. Finally, World Asset Management Inc boosted its position in Ionis Pharmaceuticals by 27.3% in the first quarter. World Asset Management Inc now owns 5,427 shares of the company’s stock worth $218,000 after buying an additional 1,163 shares during the period. 88.75% of the stock is owned by institutional investors.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

fifteen + 13 =